Hemoglobin, iron metabolism and angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study)

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 292-300

  Grammer, Tanja B ^a   Kleber, Marcus E ^a   Silbernagel, Günther ^b   Pilz, Stefan ^c   Scharnagl, Hubert ^c   Tomaschitz, Andreas ^d   König, Wolfgang ^e   März, Winfried ^a,c,f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Rehabilitation PVA Bad Aussee   (Austria)

^e UNIVERSITY OF ULM   (Germany)

^f SYNLAB ACADEMY   (Germany)

Author keywords

Coronary artery disease; Ferritin; Hemoglobin; Iron; Soluble transferrin receptor; Transferrin saturation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; HEMOGLOBIN; INSULIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; C REACTIVE PROTEIN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; IRON BLOOD LEVEL; IRON DEPLETION; IRON METABOLISM; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TRANSFERRIN BLOOD LEVEL; ANEMIA; BLOOD; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDY; GERMANY; METABOLISM; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDY; RADIOGRAPHY; SMOKING;

ADULT; AGED; ANEMIA; C-REACTIVE PROTEIN; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; FERRITINS; GERMANY; HEMOGLOBINS; HUMANS; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECEPTORS, TRANSFERRIN; SMOKING; TRANSFERRIN;

EID: 84907079126     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.002     Document Type: Article

References (60)

1. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet 1981, 1:1293-1294.
2. Kell D.B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009, 2:2.
3. Salonen J.T., Nyyssonen K., Korpela H., Tuomilehto J., Seppanen R., Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992, 86:803-811.
4. Buijsse B., Feskens E.J., Moschandreas J., Jansen E.H., Jacobs D.R., Kafatos A., et al. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil 2007, 14:495-500.
5. Yuan X.M., Brunk U.T. Iron and LDL-oxidation in atherogenesis. APMIS 1998, 106:825-842.
6. Morrison H.I., Semenciw R.M., Mao Y., Wigle D.T. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994, 5:243-246.
7. Sempos C.T., Looker A.C., Gillum R.F., Makuc D.M. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994, 330:1119-1124.
8. Sempos C.T., Looker A.C., Gillum R.E., McGee D.L., Vuong C.V., Johnson C.L. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol 2000, 10:441-448.
9. Braun S., Ndrepepa G., von Beckerath N., Vogt W., Schomig A., Kastrati A. Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis 2004, 174:105-110.
10. van der A.D., Marx J.J., Grobbee D.E., Kamphuis M.H., Georgiou N.A., van Kats-Renaud J.H., et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation 2006, 113:1942-1949.
11. Friedrich N., Milman N., Volzke H., Linneberg A., Jorgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br J Nutr 2009, 102:594-600.
12. Tuomainen T.P., Punnonen K., Nyyssonen K., Salonen J.T. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998, 97:1461-1466.
13. Haidari M., Javadi E., Sanati A., Hajilooi M., Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem 2001, 47:1666-1672.
14. Danesh J., Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999, 99:852-854.
15. Armaganijan D., Batlouni M. Serum ferritin levels and other indicators of organic iron as risk factors or markers in coronary artery disease. Rev port cardiol orgao oficial da Soc Port Cardiol - Port J Cardiol Off Journal Port Soc Cardiol 2003, 22:185-195. discussion 197-201.
16. Auer J., Rammer M., Berent R., Weber T., Lassnig E., Eber B. Body iron stores and coronary atherosclerosis assessed by coronary angiography. Nutr Metab Cardiovasc Dis 2002, 12:285-290.
17. Aronow W.S., Ahn C., Schoenfeld M.R. Serum ferritin is not a risk factor for extracranial carotid arterial disease in men and women aged > or =60 years. Am J of Cardiol 1997, 79:525-526.
18. Knuiman M.W., Divitini M.L., Olynyk J.K., Cullen D.J., Bartholomew H.C. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol 2003, 158:144-149.
19. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
20. Silverberg D.S., Wexler D., Iaina A., Steinbruch S., Wollman Y., Schwartz D. Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006, 38:295-310.
21. Anker S.D., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
22. Clark S.F. Iron deficiency anemia. Nutr Clin Pr - Off Publ Am Soc Parenter Enter Nutr 2008, 23:128-141.
23. Chonchol M., Nielson C. Hemoglobin levels and coronary artery disease. Am Heart J 2008, 155:494-498.
24. Sarnak M.J., Tighiouart H., Manjunath G., MacLeod B., Griffith J., Salem D., et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002, 40:27-33.
25. Dijk J.M., Wangge G., Graaf Y., Bots M.L., Grobbee D.E., Algra A., et al. Hemoglobin and atherosclerosis in patients with manifest arterial disease. The SMART-study. Atherosclerosis 2006, 188:444-449.
26. Reinecke H., Trey T., Wellmann J., Heidrich J., Fobker M., Wichter T., et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 2003, 24:2142-2150.
27. Lee P.C., Kini A.S., Ahsan C., Fisher E., Sharma S.K. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol 2004, 44:541-546.
28. Arant C.B., Wessel T.R., Olson M.B., Bairey Merz C.N., Sopko G., Rogers W.J., et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 2004, 43:2009-2014.
29. Lipsic E., van der Horst I.C., Voors A.A., van der Meer P., Nijsten M.W., van Gilst W.H., et al. Hemoglobin levels and 30-day mortality in patients after myocardial infarction. Int J Cardiol 2005, 100:289-292.
30. Kurek T., Lenarczyk R., Kowalczyk J., Swiatkowski A., Kowalski O., Stabryla-Deska J., et al. Effect of anemia in high-risk groups of patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2010, 105:611-618.
31. Younge J.O., Nauta S.T., Akkerhuis K.M., Deckers J.W., van Domburg R.T. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. Am J Cardiol 2012, 109:506-510.
32. Lawler P.R., Filion K.B., Dourian T., Atallah R., Garfinkle M., Eisenberg M.J. Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis. Am Heart J 2013, 165:143-153. e145.
33. Meneveau N., Schiele F., Seronde M.F., Descotes-Genon V., Oettinger J., Chopard R., et al. Anemia for risk assessment of patients with acute coronary syndromes. Am J Cardiol 2009, 103:442-447.
34. Winkelmann B.R., Marz W., Boehm B.O., Zotz R., Hager J., Hellstern P., et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2:S1-S73.
35. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975, 51:5-40.
36. Wanner C., Frommherz K., Horl W.H. Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects. Cardiology 1991, 78:202-217.
37. American Diabetes A Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
38. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996, 28:53-61.
39. Al-Ahmad A., Rand W.M., Manjunath G., Konstam M.A., Salem D.N., Levey A.S., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38:955-962.
40. Go A.S., Yang J., Ackerson L.M., Lepper K., Robbins S., Massie B.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113:2713-2723.
41. van Deursen V.M., Urso R., Laroche C., Damman K., Dahlstrom U., Tavazzi L., et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014, 16:103-111.
42. Horl W.H. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013, 9:291-301.
43. Lu K.J., Kearney L.G., Hare D.L., Ord M., Toia D., Jones E., et al. Cardiorenal anemia syndrome as a prognosticator for death in heart failure. Am J Cardiol 2013, 111:1187-1191.
44. Locatelli F., Barany P., Covic A., De Francisco A., Del Vecchio L., Goldsmith D., et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transpl 2013, 28:1346-1359.
45. Muzzarelli S., Pfisterer M., Investigators T. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006, 152:991-996.
46. Silagy C.A., McNeil J.J., Donnan G.A., Tonkin A.M., Worsam B., Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993, 54:84-89.
47. Leibovici A., Lavi N., Wainstok S., Herman J., Greene V.W. Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary care population. Can Fam Physician 1995, 41:64-68.
48. Gaskell H., Derry S., Moore R.A. Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review. BMC Geriatr 2010, 10:71.
49. Fleming D.J., Jacques P.F., Massaro J.M., D'Agostino R.B., Wilson P.W., Wood R.J. Aspirin intake and the use of serum ferritin as a measure of iron status. Am J Clin Nutr 2001, 74:219-226.
50. Cook J.D., Flowers C.H., Skikne B.S. The quantitative assessment of body iron. Blood 2003, 101:3359-3364.
51. Cook J.D., Baynes R.D., Skikne B.S. The physiological significance of circulating transferrin receptors. Adv Exp Med Biol 1994, 352:119-126.
52. Cooper M.J., Zlotkin S.H. Day-to-day variation of transferrin receptor and ferritin in healthy men and women. Am J Clin Nutr 1996, 64:738-742.
53. Tran T.N., Eubanks S.K., Schaffer K.J., Zhou C.Y., Linder M.C. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997, 90:4979-4986.
54. Pettersson T., Kivivuori S.M., Siimes M.A. Is serum transferrin receptor useful for detecting iron-deficiency in anaemic patients with chronic inflammatory diseases?. Br J Rheumatol 1994, 33:740-744.
55. Skikne B.S., Flowers C.H., Cook J.D. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990, 75:1870-1876.
56. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341:1986-1995.
57. Dunn L.L., Suryo Rahmanto Y., Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007, 17:93-100.
58. Williams M.J., Poulton R., Williams S. Ferritin and cardiovascular risk. Atherosclerosis 2003, 167:171.
59. Zegrean M. Association of body iron stores with development of cardiovascular disease in the adult population: a systematic review of the literature. Can J Cardiovasc Nurs 2009, 19:26-32.
60. Morkedal B., Laugsand L.E., Romundstad P.R., Vatten L.J. Mortality from ischaemic heart disease: sex-specific effects of transferrin saturation, serum iron, and total iron binding capacity. The HUNT study. Eur J Cardiovasc Prev Rehabil 2011, 18:687-694.